Gateways to Clinical Trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 24, Issue 8, 2002, Pages 525-552

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABCIXIMAB; ACETYLCYSTEINE; ADEFOVIR DIPIVOXIL; ALFUZOSIN; ALISKIREN; ALOSETRON; AMLODIPINE; APOMORPHINE; ATORVASTATIN; ATRASENTAN; BASILIXIMAB; BERAPROST; BEVACIZUMAB; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CELECOXIB; CETUXIMAB; CILANSETRON; CILOMILAST; DACLIZUMAB; DOCETAXEL; DULOXETINE; EFALIZUMAB; EFAVIRENZ; ELETRIPTAN; ENTECAVIR; HIRULOG; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; UNINDEXED DRUG;

ARTICLE; BENIGN TUMOR; BONE DISEASE; BREAST DISEASE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DILATATION; CORONARY STENT; DENTAL SURGERY; DRUG RESEARCH; EYE DISEASE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEMODIALYSIS; HUMAN; INFECTION; KIDNEY DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MEDICAL LITERATURE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; ORGAN TRANSPLANTATION; ORGANIZATION; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SUBCUTANEOUS TISSUE; THORAX DISEASE; URINARY TRACT DISEASE;

CLINICAL TRIALS; HUMANS;

EID: 0036815257     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (157)

1. Lincoff, A.M., Kleiman, N.S., Kottke-Marchant, K. et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for lschemic Events Trial (CACHET). Am Heart J 2002, 143 (5): 847.
2. Nakashima, H., Katayama, T., Hirano, H., Honda, Y., Suzuki, S., Yano, K. Efficacy of magnessium treatment and perfusion status before primary PTCA for acute myocardial infarction. Circ J 2002, 66 (Suppl. 1): Abst PE-150.
3. Nakashima, H., Katayama, T., Hirano, H., Honda, Y., Suzuki, S., Yano, K. Protective effects of magnesium sulphate on coronary microvascular function in acute myocardial infarction. Circ J 2002, 66 (Suppl. 1): Abst PE-149.
4. Katayama, T., Nakashima, H., Hirano, H. et al. Cardio-protective effects of intravenous magnesium sulfate for acute myocardial infarction. Circ J 2002, 66 (Suppl. 1): Abst PE-152.
5. Dens, J., Fioretti, P.M., Lopez-Sendon, J.L. et al. Impact ofenoxaparin and abciximab on bleeding complications in acute myocardial infarction: Insights from ASSENT-3. J Am Coll Cardiol 2002, 39 (5, Suppl. A): 280A.
6. Ishibashi, Y., Sakane, T., Takahashi, N. et al. Is inducible nitric oxide synthase activated in patients with ischemic heart disease? Circ J 2002, 66 (Suppl. 1): Abst PE-467.
7. Velazquez, M.T. et al. Is valsartan effective to prevent restenosis after intracoronary stent implantation? Results of a prospective, randomized study. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 322B.
8. Wong, M. et al. Effects of valsarta on left ventricular ejection fraction and diastolic diameter in patients with heart failure: ValHeFT echocardiographic study. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 202B.
9. Carson, P.E., Cohn, J.N. Effect of valsartan on time-adjusted and hospitalization frequency rate in the valsartan heart failure trial. J Am Coll Cardiol 2002, 39 (9, Suppl, B): 402B.
10. Maggioni, A.P. et al. Effects of valsartan on morbidity and mortality in HF patients not receiving ACE-inhibitors. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 401B.
11. Yamamoto, H., Nagaya, N., Miyatake, K., Ohya, H., Kangawa, K. Hemodynamic, renal and hormonal effects of ghrelin infusion in patients with chronic heart failure. Circ J 2002, 66 (Suppl. 1): Abst OJ-009.
12. Aronson, D. et al. Nesiritide improves heart rate variability in patients with decompensated heart failure. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 403B.
13. Kasama, S., Sugito, Y., Manita, M. et al. Spironolactone treatment improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. Circ J 2002, 66 (Suppl. 1): Abst OJ-320.
14. Kefer, J.M. et al. Acetylcysteine and prevention of contrast-induced reduction of renal function in patients undergoing coronary angiography. Eur J Clin Invest 2002, 32 (Suppl. 2): Abst 2.
15. Gagne, C. et al. Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 429B.
16. Davidson, M. et al. Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 135B.
17. Melani, L. et al. Ezetimibe co-administered with pravastatin in 538 patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 134B.
18. Ballantyne, C. et al. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 135B.
19. Bruckert, E., Gagne, C., Gaudet, D. et al. Homozygous familial hypercholesterolemia: Novel therapy with Ezetimibe. 73rd Eur Atheroscler Soc Congr (July 7 2002, Salzburg) 2002: Abst 239.
20. Gagne, C. et al. Ezetimibe significantly reduces low-density lipoprotein cholesterol in homozygous familial hypercholesterolemia. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 135B.
21. Lipka, L. et al. Results of ezetimibe co-administered with lovastatin in 548 patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 430B.
22. Saito, Y. et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneim-Forsch Drug Res 2002, 52(4): 251.
23. Saito, Y., Goto, Y., Dane, A., Strutt, K. Randomized, double-blind, placebo-controlled, dose-ranging study of rosuvastatin in Japanese hypercholesterolemic subjects. 73rd Eur Atheroscler Soc Congr (July 7, 2002, Salzburg) 2002: Abst 580.
24. Capuzzi, D.M., Morgan, J.M., Weiss, R., Chitra, R.R., Cressman, M.D., Hutchinson, H.G. Effects of rosuvastatin alone and combined with extended-release niacin on ApoB- and ApoA-containing lipoproteins and triglycerides in atherogenic dyslipidemia. 73rd Eur Atheroscler Soc Congr (July 7, 2002, Salzburg) 2002: Abst 214.
25. Prassl, R., Caslake, M.J., Packard, C.J. et al. Rosuvastatin enhances lipid fluidity in atherogenic apo-B containing lipoproteins. 73rd Eur Atheroscler Soc Congr (July 7, 2002, Salzburg) 2002: Abst 528.
26. Shepherd, J., Packard, C. Smith, K., Kallend, D. Evaluation of rosuvastatin in the treatment of hypercholesterolaemia in post-menopausal women. 73rd Eur Atheroscler Soc Congr (July 7, 2002, Salzburg) 2002: Abst 340.
27. Derosa, G., Mugellini, A., Cicarrelli, L., Crescenzi, G., Ghelfi, M., Fogari, R. Comparison between diet, orlistat and fluvastatin in obese patients with mild hypertension and hypercholesterolemia. 73rd Eur Atheroscler Soc Congr (July 7, 2002, Salzburg) 2002: Abst 277.
28. White, W.B., O'Connor, D.T., Hanley, A., Roniker, B., Patrick, J.L., Krause, S. Comparison of eplerenone and losartan on blood pressure lowering in low-renin hypertension. Circ J 2002, 66 (Suppl. 1): Abst PE-232.
29. Krum, H., Gordon, R.D., Nolly, H., Roniker, B., Fakouhi, K., Krause, S. Co-administration of eplerenone with an angiotensin-converting enzyme inhibitor or an angiotensin II antagonist in patients with mild to moderate hypertension. Circ J 2002, 66 (Suppl. 1): Abst PE-233.
30. Duprez, D., Lewin, A.J., St Hilaire, R., Roniker, B., Kleiman, J., Krause, S. Antihypertensive effect of eplerenone versus amlodipine in patients with elevated systolic blood pressure. Circ J 2002, 66 (Suppl. 1): Abst PE-235.
31. Kolloch, R.E., Niegowska, J., Von-Behren, V., Roniker, B., Patrick, J.L., Krause, S. Antihypertensive effect of eplerenone and enalapril in patients with essential hypertension. Circ J 2002, 66 (Suppl. 1): Abst PE-236.
32. Timar, O. et al. Effect of irbesartan on microcirculation in hypertensive patients with metabolic syndrome X. Eur J Clin Invest 2002, 32 (Suppl, 2): Abst 78.
33. Watanabe, H., Ohashi, K., Yamashita, K. et al. A potential role of sildenafil in the management of pulmonary hypertension. Circ J 2002, 66 (Suppl. 1): Abst PE-206.
34. Gowda, S. et al. Improved survival in cardiac transplant recipients treated with the anti interleukin-2 receptor of basiliximab. Am J Transplant 2002, 2 (Suppl. 3): Abst 440.
35. Schenker, H.I., Williams, L., Goode, S.M. et al. Iris pigmentation changes following treatment with travoprost or latanoprost in patients with open-angle glaucoma or ocular hypertension. Annu Meet Assoc Res Vision Ophthalmol (May 5, 2002, Fort Lauderdale) 2002: Abst 3431.
36. Zuberi, B. et al. Octreotide in hepatorenal syndrome: A randomized study. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.X.018.
37. Lee, T. et al. Effect of CYP2C19 polymorphism on esophageal pH during rabeprazole administration. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P: A.098.
38. Lindor, N.M., Dozois, R., Nelson, H. et al. Desmoid tumors in familial adenomatous polyposis: A pilot project evaluating treatment with pirfenidone. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst W1249.
39. Daperno, M. et al. Role of infliximab in the treatment of acute ulcerative colitis: A pilot study on 6 patients. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.E.036.
40. Baumgart, D.C., Pascu, M., Wiedenmann, B., Dignass, A.U. Rescue therapy with tacrolimus (FK506) is highly effective in patients with severe and refractory inflammatory bowel disease. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst T1211.
41. Sloots, C.E.J., Poen, A.C., Kerstens, R. et al. Effects ofprucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002, 16(4): 759.
42. Van Assche, G. et al. MRI imaging of the effects of infliximab in perianal fistulizing Crohn's disease. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.E.009.
43. Duvnjak, M., Virovic, L. Efficacy of inflixumab in Crohn's disease: A comparison of clinical and laboratory parameters. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.E.079.
44. Babu, S. et al. Infliximab treatment for Crohn's disease reduces hospital costs in the long term. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.E.087.
45. Sabate, J.M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M., Modigliani, R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002, 16(6): 1117.
46. Sabate, J.M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M., Modigliani, R. An open-label study on thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst T1654.
47. Arrigoni, A. et al. Response to infliximab in "acute" and in refractory colonic Crohn's disease: A preliminary experience. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst PE.008d.
48. Sandborn, W.J., Present. D.H., Isaacs, K.L. et al. Tacrolimus (FK506) for the treatment of perianal and enterocutaneous fistulas in patients with Crohn's disease: A randomized, double-blind, placebo-controlled trial. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst 670.
49. Bauditz, J., Wedel, S., Lochs, H. Thalidomide for treatment of intestinal bleeding: Correlation to VEGE. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst S 1262.
50. Bariol, C., Meagher, A.P., Vickers, C.R. et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002, 17(2): 135.
51. Bauditz, J., Wedel, S., Lochs, H. Thalidomide reduces tamour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002, 50(2): 196.
52. Vinh, N.T. et al. Safety of a Cox-2 specific inhibitor in Helicobacier pylori (HP) infected non-ulcer dyspepsia (NUD) patients in Vietnam. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.B.098.
53. Leodolter, A. et al. Helicobacter pylori and female gender are more predictive of non-erosive vs erosive gastroesophageal reflux disease (GERD): An analysis based on the ProGERD study initiative. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.093
54. Trudgill, N.J., Hussain, F.N., Moustafa, M., Ajjan, R., D'Amato, M., Riley, S.A. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease. Aliment Pharmacol Ther 2002. 15(9): 1357.
55. Hammer, J., Hammer, H. Rabeprazole 20 mg once daily in the treatment of young and ederly patients with symptomatic gastroesophageal reflux disease. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.023.
56. Johanson, J. et al. Rabeprazole effectively relieves moderate to severe heartburn in symptomatic GORD. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.039.
57. Hammer. H. et al. Rabeprazole efficacy, in GORD: Analyses from 3 community-based open-label international trials. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.044.
58. Clemens, C.H.M., Samsom, M., van Berge Henegouwen, G.P., Fabri, M., Smout, A.J.P.M. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2002, 16(5): 993.
59. Caras, S., Carter, F., Algood, A., Driessen, S., Krause, G., Steinborn, C. Cilansetron shows as increase in adequate relief rate in non-constipated IBS subjects who respond as having no adequate relief at baseline. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst W 1019.
60. Kato, H. Effect of rabeprazole on healing process of gastric ulcer in an early phase and CYP2C19 polymorphism. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.C.038.
61. Koliouskas, D. et al. Comparative analysis of Peg-Interferon alpha-2b hepatitis B patients: Preliminary results. J Hepatol 2002, 36 (Suppl. 1): Abst 851.
62. Peters, M., Hann, H.W., Martin, P. et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 Week interim analysis. J Hepatol 2002, 36 (Suppl. 1): Abst 13.
63. Marcellin, P., Goodman, Z., Chang, T.-T. et al. Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil. J Hepatol 2002, 36 (Suppl. 1): Abst 18.
64. Marcellin, P., Chang, T.T., Lim, S.G. et al. Baseline ALT predicts histologic and serologic response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV). J Hepatol 2002, 36 (Suppl. 1): Abst 436.
65. Yang, H., Westland, C., Delaney, W. IV. et al. Lack of emerging resistance mutations in 467 HBeAg- and HBeAg+ patients with chronic hepatitis B receiving adefovir dipivoxil for 48 weeks. J Hepatol 2002, 36 (Suppl. 1): Abst 493.
66. Westland, C., Delaney, W., Yang, H. et al. Distribution and clinical response of HBV genotypes in phase III studies of adefovir dipivoxil. J Hepatol 2002, 36 (Suppl. 1): Abst 370.
67. Brosgart, C., Fry, J., Xiong, S. et al. Adefovir dipivoxil (ADV) for the treatment of chronic HBV infection. Antivir Res 2002, 53(3): Abst 151.
68. Heathcote, E., Jeffers. L., Perrillo, R. et al. Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection. J Hepatol 2002, 36 (Suppl. 1): Abst 391.
69. Hadziyannis, S., Tassopolous, N., Heathcote, E. et al. GS-98-438 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 Week results. J Hepatol 2002, 36 (Suppl. 1): Abst 5.
70. Cooksley, H., Chokshi, S., Wedemeyer, H. et al. Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: A multicentre, controlled study. J Hepatol 2002, 36 (Suppl. 1): Abst 16.
71. Thibault, V., Benhamou, Y., Bochet, M., Kalkias, L., Xiong, S., Brosgart, C. Long term use of adefovir in HIV-HBV coinfected patients is not associated with emergence of specific HBV polymerase mutations. J Hepatol 2002, 36 (Suppl. 1): Abst 474.
72. Benhamou, Y., Bochet, M., Thibault, V. et al. Safety and efficacy of long-term adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in HIV infected patients. J Hepatol 2002, 36 (Suppl. 1): Abst 496.
73. Roche, B., Roque-Afonso, A.-M., Feray, C., Duclos-Vallee, J.-C., Bismuth, H., Samuel, D. Adefovir therapy for HBV infection after liver transplantation (LT). J Hepatol 2002, 36 (Suppl. 1): Abst 129.
74. Shakil, A.O., Lilly, L., Angus, P. et al. Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for chronic hepatitis B infection. J Hepatol 2002, 36 (Suppl. 1): Abst 433.
75. Schiff, E., Neuhaus, P., Tillman, H. et al. Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients. J Hepatol 2002, 36 (Suppl. 1): Abst 94.
76. Li, J. et al. PEG-IFN and increase of weight based ribavirini dosing are associated with increased risk of anemia. J Hepatol 2002, 36 (Suppl. 1): Abst 613.
77. Chung, R. et al. A randomized, controlled trial of pegylated interferon alpha-2a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071. 9th Conf Retroviruses Opportunistic Infect (Feb 24, 2002, Seattle) 2002: Abst LB15.
78. Albin, R., Green, G., Hamilton, D. et al. A pilot study of the safety and efficacy of intranasal ketamine for the treatment of postoperative dental pain. Clin Pharmacol Ther 2002, 71(2): Abst MP1-45.
79. Reading, C.L., Khoury, G., Giese, T., Frincke, J.M. Immune changes observed following 16-alpha-bromo-epiandrosterone (HE2000) treatment of HIV-1-infected individuals. 14th Int AIDS Conf (July 7, 2002, Barcelona) 2002: Abst MoPeA3041.
80. Benson, C.A. et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002, 185(5): 599.
81. Grover, S.A., Brewer, S.A., Gilmore, N., Mukherjee, J., Giordano, M. Dyslipidemia associated with highly active antiretroviral therapy (HAART) for HIV infections: Estimating the impact of nelfinavir and atazanavir on cardiovascular (CVD) risk and mortality. 73rd Eur Atheroscler Soc Congr (July 7, 2002, Salzburg) 2002: Abst 586.
82. Beniowski, M. et al. CHARM: A phase III open-label, randomized, multi-center study to evaluate the efficacy and tolerability of adding nevirapine (NVP) and/or hydroxyurea (HU) to a triple-nucleoside-based antiretroviral drug regimen in treatment-naïve HIV-1-infected subjects. 9th Conf Retroviruses Opportunistic Infect (Feb 24, 2002, Seattle) 2002: Abst 410-W.
83. Pollard, R. et al. Stavudine XR vs stavudine 1R as a part of potent antiretroviral combination therapy: 24-Week safety and antiviral efficacy. 9th Conf Retroviruses Opportunistic Infect (Feb 24, 2002, Seattle) 2002: Abst 411-W.
84. Coetzee, N. et al. A randomized, placebo-controlled, double-blind expanded safety trial of Carraguard(TM) microbicide gel in South Africa: Signs and symptoms of genital irritation. 14th Int AIDS Conf (July 7, 2002, Barcelona) 2002: Abst WeOrD1316.
85. Hoosen, A. et al. A randomized, placebo-controlled, double-blind expanded safety trial of Carraguard(TM) microbicide gel in South Africa: RT1/ST1 at baseline and follow-up. 14th Int AIDS Conf (July 7, 2002, Barcelona) 2002: Abst WePpD6414.
86. Blanchard, K. et al. A randomized, placebo-controlled double-blind expanded safety trial of Carraguard(TM) microbicide gel in South Africa: Study gel acceptability. 14th Int AIDS Conf (July 7, 2002, Barcelona) 2002: Abst MoPeD3551.
87. Philotheou, A., Distiller, L., Bonnici, F. et al. A randomized, double-blind, placebo-controlled, multi-center sequential, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of NBI-6024 in adolescent patients with insulin dependent type I diabetes mellitus. Diabetes 2002, 51 (Suppl. 2): Abst 453-P.
88. Juhl, C.B., Hollingdal, M., Sturis, J. et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51(2): 424.
89. Gokcel, A. et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002, 4(1): 49.
90. Reginster, J., Bias, P., Buchner, A. First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX for the treatment of osteoarthritis. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0189.
91. Shiraki, M. et al. A double-blind dose-ranging study of risedronate in Japanese patients with involutional osteoporosis. Osteoporosis Int 2002, 13 (Suppl. 1): Abst P93SU.
92. Devogelaer, J.P. et al. Risedronate is an effective therapy for men receiving glucocorticoid therapy. Eur J Clin Invest 2002, 32 (Suppl. 2): Abst 69.
93. Devogelaer, J.P. et al. Risedronate is effective and well tolerated in treating corticosteroid-induced osteoporosis. Eur J Clin Invest 2002, 32 (Suppl. 2): Abst 71.
94. Modlin, I. et al. The utility of octreotide and isotopes in the diagnosis and treatment of neuroendocrine tumors (NETs). J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.D.023.
95. Drake, M., Robson, W., Neal, D.E., Leung, H.Y. Low dose thalidomide in androgen independent prostate cancer. Eur Urol Suppl 2002, 1(1): Abst 627.
96. Kallich, J. Darbepoetin alfa has higher observed improvements fatigue and physical well being than epoetin alfa. 7th Congr Eur Haematol Assoc (June 6, 2002, Florence) 2002: Abst 0262.
97. Harris, N., Crook, T., Hicks, J. et al. Intravesical meglumine γ-linolenic acid: A phase IIa efficacy study. Eur Urol Suppl 2002, 1 (1): Abst 481.
98. Harris, N.M., Crook, T.J., Bass, P. et al. Intravesical meglumine γ-linolenic acid: A phase 2a efficacy study. J Urol 2002, 167 (4, Suppl.): Abst 758.
99. Schulman, C., Nelson. J.B., Weinberg, M.A. et al. Atrasentan delayed PSA progression in a phase II trial of men with hormone refractory prostate cancer. J Urol 2002, 167 (4, Suppl.): Abst 705.
100. Schulman, C., Abrahamsson, P., Humerickhouse, R., Weinberg, M., Schmitt, J., Nabulsi, A. Metastatic, hormone refractory prostate cancer: A randomised phase II study of the endothelin-A receptor antagonist atrasentan. Eur Urol Suppl 2002, 1(1): Abst 620.
101. Bracarda, S., Lippe, P., Contu, A. et al. Docetaxel (D), estramustine (E), dexamethasone (DEX) and prednisone (P) in chemo and/or radiotherapy pretreated hormone refractory, prostate cancer patients (HRPC): A preliminary phase II study. Eur Urol Suppl 2002, 1(1): Abst 626.
102. Guimaraes, T., Bento, M.J., Pinho, T., Guedes de Carvalho, R., Pinto, F. Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer. Eur Urol Suppl 2002, 1(1): Abst 625.
103. Fred, S., Gleason, D., Murray, R. et al. Zoledronic acid significantly reduces fractures in patients with hormone-refractory prostate cancer metastatic to bone. J Urol 2002, 167 (4, Suppl.): Abst 703.
104. Langmuir, V.K., Cobleigh, M.A., Herbst, R.S. et al. Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 32.
105. Saltz, L., Meropol, N.J., Loehrer, P.J., Waksal, H., Needle, M.N., Mayer, R.J. Single agent IMC-C225 (Erbitux(TM)) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 504.
106. Evans, T.L., Fidias, P., Skarin, A. et al. A phase II study of efficacy and tolerability of the farnesyl-protein transferase inhibitor, L-778,123 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002. 21 (Part 2): Abst 1861.
107. Kindler, H.L. II., Dugan, W., Hochster, H., Strickland, D., Jacobs, A., John, W.J. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 499.
108. Markovic, S.N., Suman, V.J., Vukov, A.M. et al. Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol 2002, 25(3): 308.
109. Murray, V. et al. Sertraline for poststroke depression - A controlled study. Stroke 2002, 33(1): Abst P292.
110. Schurch, B., Tenti, G., Reitz, A. Electromotive drug administration of lidocaine to anesthetise the bladder before botulinum toxin-A injections into the detrusor. Eur Urol Suppl 2002, 1(1): Abst 574.
111. Stark, R., Dahlöf, C., Haughie, S., Hettiarachchi, J. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: Results of a phase 111, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002, 22(1): 23.
112. Smith, D.R. et al. Randomized trial of pulse cyclophosphamide in IFN-B resistant active MS. 54th Annu Meet Am Acad Neurol (April 13, 2002, Denver) 2002: Abst P06.073.
113. Conti, M., Sandercock, P., Gandolfo, C. Lubeluzole for acute ischaemic stroke. A systematic review. Cerebrovasc Dis 2002, 13 (Suppl. 3): Abst P281.
114. Tschugguel, W. et al. Combined vaginal treatment with the nitric oxide donor isosorbide mononitrate and the prostaglandin E1 analog gemeprost versus application of placebo and gemeprost for termination of second-trimester pregnancy: A planned interim analysis of a multicenter: Prospective randomized, double-blind placebo-controlled trial. J Soc Gynecol Invest 2002, 9 (1, Suppl.): Abst 762.
115. Goldstein, D.J. et al. Duloxetine in the treatment of major depressive disorder: A randomized double-blind clincial trial. J Clin Psychiatry 2002, 63(3): 225.
116. Detke, M.J. et al. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002, 63(4): 308.
117. Kasper, S., Wolf, R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol 2002, 12(2): 119.
118. Radziszewski, P., Borkowski, A. Botulinum toxin type A intravesical injections for intractable bladder overactivity. Eur Urol Suppl 2002, 1(1): Abst 526.
119. Pinggera, G.M., Schuster, A., Pallwein, L. et al. Alpha-Blockers increase vesical and prostatic blood flow and bladder capacity. J Urol 2002, 167 (4, Suppl.): Abst 1485.
120. Glémain, P., Coulange, C., Grapin, F.N., Muszynski, R.C. No benefit in combining tamsulosin with Serenoa repens versus tamsulosin alone on storage/filling and voiding lower urinary tract symptoms. J Urol 2002, 167 (4, Suppl.): Abst 1486.
121. Diamond, S.M., Hubosky, S., El-Gabry, E, Switching men with enlarged prostates and LUTS to finasteride after initial treatment with alpha blockade. J Urol 2002, 167 (4, Suppl.): Abst 1490.
122. Diamond, S.M., Ismail, M., Hubosky, S., El-Gabry, E. Placebo controlled trial of alpha blockade and finasteride in men with enlarged prostates and LUTS: Subjective and objective results after discontinuation of alpha blockade. J Urol 2002. 167 (4, Suppl.): Abst 1484.
123. Speakman, M. Tamsulosin reduces the risk of acute urinary reten tion. J Urol 2002, 167 (4, Suppl.): Abst 1492.
124. Lucas, M., Stephenson, T., Vinod, N. Tamsulosin in the management of patients in acute urinary retention due to benign prostatic hyperplasia. Eur Urol Suppl 2002, 1(1): Abst 415.
125. Lucas, M., Stephenson, T.P., Nargund, V. Tamsulosin reduces the need for recatheterisation following an episode of acute urinary retention in elderly benign prostatic hyperplasia patients. J Urol 2002, 167 (4, Suppl.): Abst 1047.
126. Francos, G.C. et al. Double-blind, placebo-controlled, 3 year study of steroid withdrawal using a Neoral and mycophenolate mofetil (MMF)-based immunosuppressive regimen in primary renal transplant recipients. Am J Transplant 2002, 2 (Suppl. 3): Abst 137.
127. Benfield, M. et al. Comparative study of the safety, efficacy, and practice patterns of monoclonal antibodies (mAbs) in pediatric renal transplantation (PRT). Am J Transplant 2002, 2 (Suppl. 3): Abst 213.
128. Sandrini, S. et al. Basiliximab facilitates steroid withdrawal after renal transplantation: Results of an Italian, multicentre, placebo-controlled study (Swiss study). Am J Transplant 2002. 2 (Suppl. 3): Abst 136.
129. Koch, M. et al. Long term results of basiliximab in renal transplantation. Am J Transplant 2002, 2 (Suppl. 3): Abst 1020.
130. Inston, N.G. et al. Basiliximab reduces acute allograft rejection in high risk renal transplant recipients. Am J Transplant 2002, 2 (Suppl. 3): Abst 1033.
131. Heaton, J., Sleep, D., Perdok, R., Reseek, M.E. Safety of Uprima (apomorphine SL) 2 and 3 mg in men with erectile dysfunction (ED) concurrently taking nitrate medication. Eur Urol Suppl 2002, 1(1): Abst 601.
132. Hutter, A.M. Jr., Kloner, R.A., Watkins, V. et al. Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor. Am J Hypertens 2002, 15 (4, Part 2): Abst P-302.
133. Mitwally, M.F. et al. Aromatase inhibition for ovarian stimulation: Summary, of two years experience. J Soc Gynecol Invest 2002, 9 (1, Suppl.): Abst 307.
134. Rossouw, J.E., Anderson, G.L., Prentice, R.L. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3): 321.
135. Lowe, F., Djavan, B. Prospective, randomized trial to evaluate the side effect profile of tamsulosin vs terazosin in 1983 men with benign prostatic hyperplasia. J Urol 2002, 167 (4, Suppl.): Abst 1052.
136. Narayan, P., Djavan, B. Prospective, randomized multicenter trial of tamsulosin vs terarosin to evalute the velocity of the onset of action. J Urol 2002, 167 (4, Suppl.): Abst 1497.
137. O'Leary, M. Tamsulosin demonstrates long-term efficacy on multiple clinical and quality-of-life scoring systems. J Urol 2002, 167 (4, Suppl.): Abst 1491.
138. Narayan, P., McKay, J., Doyle, C. A six-week double-blind pilot study of tamsulosin versus placebo in patients with chronic non-bacterial prostatitis/chronic pelvic pain. J Urol 2002, 167 (4, Suppl.): Abst 97.
139. Leichtl, S., Schmid-Wirlitsch, C., Bredenbröker, D., Rathgeb, F., Wurst, W., Gulden. B. Dose-related efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor; in asthma. 98th Int Conf Am Thorac Soc (May 17, 2002, Atlanta) 2002: Abst A23.
140. Bredenbröker, D., Syed, J., Leichtl, S., Rathgeb, F., Wurst, W., Gulden, B. Safety of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in patients with COPD. 98th Int Conf Am Thorac Soc (May 17, 2002, Atlanta) 2002: Abst C92.
141. Kelsen, S.G., Rennard, S.I., Chodosh. S., Schryver, B., Vleisides. C., Zhu, J. COPD exacerbation in a 6-month trial of cilomilast (Ariflo(R)) a potent, selective phosphodiesterase 4 inhibitor. 98th Int Conf Am Thorac Soc (May 17. 2002. Atlanta) 2002: Abst 316.
142. Gottlieb, A.B., Krueger, J.G., Wittkowski, K., Dedrick, R., Walicke, P.A., Garovoy, M. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002. 138(5): 591.
143. Lowe, N.J., Lask, G., Yamauchi, P. Efficacy and safety of botulinum toxins A and B for the reduction of glabellar rhytids in female subjects. 60th Annu Meet Am Acad Dermatol (Feb 22, 2002, New Orleans) 2002: Abst P459.
144. Dzavik, V., Jackevicius, C., Ross, J. et al. In-hospital outcome is improved in women after percutaneous coronary intervention and is similar to that in men in the era of routine platelet glycoprotein 11b/111a inhibition and stenting. J Am Coll Cardiol 2002, 39 (5, Suppl. A): 455A.
145. Agarwal, A. et al. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2002, 2 (Suppl. 3): Abst 873.
146. Vieira, C.A. et al. Rituxan for reduction of anti-HLA antibodies in patients awaiting renal transplantation. Am J Transplant 2002, 2 (Suppl. 3): Abst 870.
147. Agarwal, A. et al. Effect of rituximab on natural antibodies in pretransplant recipients. Am J Transplant 2002. 2 (Suppl. 3): Abst 825.
148. Jeffery, J.R. et al. Impact of adding basiliximab to cyclosporine, mycophenolate mofetil and prednisone based immunosuppression on clinical and subclinical rejection. Am J Transplant 2002, 2 (Suppl. 3): Abst 1078.
149. Sudan, D. et al. Basiliximab decreases the incidence of acute rejection after intestinal transplantation. Am J Transplant 2002, 2 (Suppl. 3): Abst 946.
150. Nussberger, J. et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril. Hypertension 2002, 39(1): E1.
151. Kuo, B., Camilleri, M., Burton, D. et al. Effects of 5-HT3 antagonism on postprandial gastric volume and symptoms in humans. Aliment Pharmacol Ther 2002, 16(2): 225.
152. Onodera, S. Lafutidine, a novel histamine H2 receptor antagonist, inhibits daytime acid secretion in both H. pylori infected and non-infected human subjects. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.C.008.
153. Saitoh, T. et al. Lafutidine, a novel histamine H2 receptor antagonist, inhibit daytime acid secretion in both H. pylori infected and non-infected human subjects. J Gastroenterol Hepatol 2002. 17 (Suppl.): Abst P.C.078.
154. Klesser, B., Bias, P., Buchner, A. Licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, has little or no effect on the gastric mucosa after 4 weeks of treatment. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst THU0243.
155. De Schryver. A.M.P., Amdriesse, G.I., Samsom, M., Smout, A.J.P.M., Gooszen, H.G., Akkermans, L.M.A. The effects of the specific 5HT4 receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002, 16(3): 603.
156. Rahme, E. et al. Gastrointestinal complications associated with rofecoxib/celecoxib and other nonselective NSAIDs: Analysis of the govenment claims database in Quebec, Canada. Eur Leag Against Rheum Congr (June 12, 2002, Stockholm) 2002: Abst AB0531.
157. Ishikura, F., Toshida, T., Iwata, A., Asanuma, T., Beppu, S. Noninvasive evaluation of left anterior descending coronary flow after sildenafil citrate (Viagra) administration by Doppler echocardiography in normal subjects. Circ J 2002, 66 (Suppl. 1): Abst PJ-153.